Tempest Therapeutics Secures $2.0M in Warrant Exercise, Issues New Warrants for Future Dilution
TPST is trading near its 52-week low of $1.45 (1.4% below the low).
Summary
Tempest Therapeutics raised $2.0 million by inducing a warrant exercise, but issued new warrants for over 2.3 million shares, signaling a highly dilutive financing to address its critical liquidity needs.
Key Events · Financing and Capital Events · TPST
-
Warrant Exercise & Proceeds
A holder exercised 1,172,414 existing warrants for $2.0 million in gross proceeds. The original warrants, issued in November 2025 with an adjusted exercise price of $1.75 (after the 2:1 forward split on 2026-01-30), were exercised at a reduced price of $1.73 per share.
-
New Warrant Issuance
The company issued new unregistered warrants to purchase 2,344,828 shares (200% of the exercised amount) at an exercise price of $1.73 per share. These new warrants require stockholder approval and will expire on May 29, 2028.
-
Critical Liquidity
This capital raise provides essential funds for a company with a 'going concern' warning and recent Nasdaq deficiency notices, extending its cash runway from a reported $1.8 million in Q1 2026.
-
Significant Dilution
The issuance of new warrants represents substantial potential future dilution for existing shareholders, reflecting the company's urgent need for capital. The new warrants are priced at $1.73, above the current stock price of $1.43.
Analysis · TPST · Life Sciences
Tempest Therapeutics, facing a 'going concern' warning and Nasdaq deficiency notices, has secured $2.0 million in immediate liquidity by inducing a warrant holder to exercise existing warrants. While this provides critical cash, the company issued new warrants for 2.34 million shares (200% of the exercised amount) at an exercise price of $1.73, which represents significant potential future dilution for existing shareholders. This transaction is a necessary step to extend the company's cash runway and address its financial challenges, especially as the stock trades near its 52-week low.
At the time of this filing, TPST was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5M. The 52-week trading range was $1.45 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.